Shanghai Xingkang Pharmaceuticals Research & Development Co., Ltd. is a foreign-capital enterprise founded in July of 2001 and invested by Rowell Overseas Holding Limited. The company is located in the Zhangjiang Hi-Tech Park in Pudong New Area in Shanghai with a 1300m2 R&D facility. Xingkang-Pharm specializes in development of new drug candidates, novel drug delivery systems and cutting-edge technologies. Additionally, we offer technical support and a variety of other services to domestic and global pharmaceutical companies. Xingkang-Pharm has earned its reputation as an advanced pharmaceutical R&D organization by providing high quality services through th years. During the past six years, under the management team led by the distinguished professor Zheng Liangyuan, Xingkang-Pharm has established state of the art R&D laboratories specializing in a variety of drug delivery technologies. Combined with the GMP capacity of Cinmed Pharmaceutical Co. Ltd, a sister company founded by the same investor, we have the ability to develop drug products from bench top to full manufacturing scale. In addition to formulation development, we also provide scale-up, technical transfer and manufacturing services. The mission of Xingkang-Pharm is to rapidly develop and market the best products that bring superior value to its customers.

The success of Xingkang-Pharm hinges on its people and advenced technologies. Xingkang-Pharm has an excellent R&D team that consists of 60% senior engineers and researchers with doctorate or master’s degrees. The aim of the compony is to create a culture to hire and maitain the best people and to employ pharmaceuticals techninologies driven by innovation. Up to now, we have established 7 novel drug delivery platforms and filed four patents (1 USA patent, 3 Chinese patents). In addition, we have had more than 10 new drugs approved by the SFDA, including sulphonated dehydrogenated sylvate, an insulin dry powder inhalation system, an ophthalmic in situ forming gel. They are all leading products in China. We also have many new products which are undergoing R&D or are ready for application at present.

Based on our incessant hard-work and good reputation, Xingkang-Pharm has established close, cooperative relationships with many renowned universities and pharmaceutical companies, such as China Pharmaceutical University, Shenyang Pharmaceutical University, Sun Yat-Sen University and the Shanghai Institute of Pharmaceutical Industry to name a few. The advanced technologies and growth potential of Xingkang-Pharm have also attracted several well-known international enterprises as collaborating partners, including Diosna, Glatte, Degussa, Colorcon and ISP. In conclusion, we value our customers, and we strive to meet their needs by providing the best quility products and services.

Structure of laboratory:

Novel Technology Platforms
1. Ophthalmic in situ Forming Gel
2. Fast Disintigration in Mouth with Taste-Masking
3. Dry Powder Inhalation (Nasal and Pulmonary)
4. Sustained Release Micro-Granules
5. Control Release (once daily)
(1) Osmotic Pump with Modified Release
(2) Membrane Control
6. Timed Pulsatile Release
7. Drug Stabilization

Flow Chart for Project R&D Process